In patients with MINOCA & ANOCA coronary microvascular disease portends a worse outcome. Classification & outcomes of coronary microvascular disease in myocardial infarction and angina with non-obstructive coronary arteries @MayoClinicCV@claireraph https://t.co/7X7W5DSCrE
Systematic post-PCl functional assessment is associated with a significant reduction in 12-month MACE. 1-Year Results of the PROPHET-FFR Study. Presented @sicigise 47th National Congress and published simultaneously @enromagnoli@GianlucaCampo78
https://t.co/agUgIwEjEu
High-potency P2Y12 inhibitors among patients with chronic coronary syndrome undergoing PCI: An analysis from the NCDR CathPCI Registry. Substantial inter-hospital variation persists despite the guidelines @esbrilakis @Jennifer_rymer @islamelgendy83 https://t.co/SsG28Mx3EG
📣Calling all #AHFTC Fellows!📣
@CircHF is proud to launch the 2nd year of the journal's free educational webinar series for current & past AHFTC fellows
📌9 live virtual sessions
📌New topic each session
📅Start Date: November 18, 2026
🔗Learn More: https://t.co/9fJ1SN4zLd
📣 #Stroke Bridge Seminar: Advancing Stroke Intervention: From Device Innovation to Clinical Practice
🗓️ Tuesday, October 6, 2026, 12:00-1:00 PM PDT | 19:00-20:00 UTC
🌟 Speakers: @JeremyHeitMDPHD & Matthew J. Gounis
🌟 Hosted by @Chenhsbbb
📎Register: https://t.co/AU1PKjjQ7N
2/ Paclitaxel-coated devices did not improve limb salvage in patients with CLTI and tissue loss
@iiijohan @WallinderJ @fredriksellgren https://t.co/fqvSaMVjet
1/ Paclitaxel-coated devices in patients with chronic limb threatening ischemia and tissue loss undergoing infrainguinal endovascular revascularization: Insights from the SWEDEPAD-1 trial. ...
Contrasting Prognostic Value of Discordance Between Resting Distal-to-aortic Coronary Pressure Ratio and Fractional Flow Reserve in Coronary Artery Disease. FFR predicts Vessel-specific events. Resting Pd/Pa predicts Overall survival @dukwoo_park
https://t.co/eqPuVOfWxH
Where AI meets the plaque. Artificial intelligence-derived volumetric high-risk plaque features are predominantly located proximal to maximal luminal stenosis @RickVolleberg https://t.co/1R6kKxKSzH
Influence of Chronic Kidney Disease on Outcomes Following Paclitaxel-Coated Balloon Angioplasty for Coronary In-Stent Restenosis. An AGENT IDE Subgroup Analysis. CKD did not influence outcome @rwyeh@ajaykirtane@mobitz@bigboy1202 @behnam_tehrani https://t.co/zNjTu4BJTU
What happens to TR following M-TEER? Impact of Tricuspid Regurgitation on Outcomes after Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation: The PRIME-MR Registry @AndreaScotti21@azeemlatib@AugustinCoisne@modine_thomas@jgranadacrf
https://t.co/g7Tn5MHJay
2/ Long-term outcomes depend on baseline clinical status & lesion complexity, not the technique @LAzzaliniMD@giampieroviz@Simone_Zecchino @Massimo_Leoncini @dariocalderone https://t.co/GQ9mUXo8tS
1/ Minicrush or T-stenting & minimal protrusion in complex coronary bifurcation lesions: The Multicenter T-REX registry. Minicrush is associated with a lower risk of stent thrombosis, but overall comparable target lesion failure & adverse event rates. ...
Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, & Response to TAVR: Insights from Egnite Data. TAVR alone reduces mitral regurgitation in most patients @PhilGenereuxMD@benpeterson71@TsuyoshiKaneko@DLBhattMD https://t.co/bFUuQqXSNP
Aberrant, Elevated Papillary Muscle & LV Wall Forces Associated with Mitral Valve Prolapse are Normalized by Surgical Neochordal Repair but not by Transcatheter Edge-to-Edge Repair @AlexanderReedMD https://t.co/ZTVGXdadfY
2/ Failed-BEV had more SVD, fewer PVL & longer time to reintervention vs failed-SEV with no difference in 3-year mortality after redoTAVR or TAVR-explant #cardiotwitter@SyedZaidMD@GilbertTangMD
https://t.co/ZvaV9A4CGf
The diagnostic accuracy to identify culprit arteries using coronary angiography in women with MINOCA is poor. More OCT? Accuracy of Angiographic Identification of Culprit Lesions in Women with MINOCA @BinitaShahMD
https://t.co/i5PPhLiIgl
Contemporary Trends for the Treatment of In-Stent Restenosis in the United States. Adjunctive plaque-modification devices has increased substantially associated with higher in-hospital adverse event rates @schuyler_jones @Jennifer_rymer @TessAllanMed https://t.co/8gf5VCBIe2